Senior Management Changes

GlaxoSmithKline PLC
15 October 2002



Issued - Tuesday 15 October 2002, London & US




                      GlaxoSmithKline's Ingram To Retire;
             Stout Appointed President, Pharmaceuticals Operations



GlaxoSmithKline plc (GSK) announces that Robert A. Ingram, currently Chief
Operating Officer and President, Pharmaceutical Operations, will retire from
that position effective 31st December 2002. He will continue to work part-time
as Vice-Chairman of Pharmaceuticals, acting as a special advisor to the Group
and representing GSK on the board of the US Pharmaceutical Research and
Manufacturers' Association (PhRMA).


David Stout, currently President, US Pharmaceuticals, will be named President,
Pharmaceuticals Operations and will report to Jean-Pierre Garnier, Chief
Executive Officer. Mr. Stout will be responsible for management of the Group's
global pharmaceuticals business, and will be based at GSK's offices in
Philadelphia, PA.


David Stout will be succeeded as President, US Pharmaceuticals by Chris
Viehbacher, currently President, Pharmaceuticals, Europe. Chris Viehbacher will
be based at GSK's offices in Research Triangle Park. Andrew Witty, currently
Senior Vice President, Asia Pacific, will succeed Chris Viehbacher as President,
Pharmaceuticals, Europe. He will be based at the company's corporate
headquarters in London. Chris Viehbacher and Andrew Witty will report to David
Stout.

Jean-Pierre Garnier said: "Bob Ingram is a true statesman and an unrivalled
ambassador for both GSK and the pharmaceutical industry. He is admired as a role
model and leader within GSK, and is recognised as an outstanding representative
of both our company and our industry by the people he works with outside GSK. We
are delighted that Bob will continue to use his considerable talents on behalf
of our company as Vice Chairman of Pharmaceuticals. I would like to personally
thank Bob - and pass along the thanks and best wishes of all our employees - for
his many contributions to GSK, in particular his strong leadership, wisdom and
guidance throughout the integration process".

Today, GSK is well positioned to manage our future challenges and opportunities.
Our new appointees will continue to strengthen our management team as they bring
the breadth and depth of their experience and perspective to bear in their new
roles. I would like to congratulate them on their appointments, and look forward
to working with this executive team in 2003."

Bob Ingram said: "I have immensely enjoyed the many years I have worked in an
industry that makes such a difference in improving the lives and health of so
many people throughout the world. In particular, I have always considered it an
honour to work with GSK's management team and employees, all of whom exhibit
such a high quality of professionalism, expertise and dedication. These are very
special people, working at a very special company, in a very special industry.
For that reason, I am very proud to have the opportunity to continue working on
behalf of GSK."

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.









Enquiries:

UK Media enquiries:                     Martin Sutton            [phone]
                                        Alan Chandler            [phone]
                                        Siobhan Lavelle          [phone]

US Media enquiries:                     Nancy Pekarek            [phone]
                                        Mary Anne Rhyne          [phone]
                                        Patricia Seif            [phone]

European Analyst/Investor enquiries:    Duncan Learmouth         [phone]
                                        Philip Thomson           [phone]
                                        Joan Toohill             [phone]

US Analyst/ Investor enquiries:         Frank Murdolo            [phone]
                                        Tom Curry                [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange